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Aims: To examine the prevalence of potentially hazardous prescribing in the prison
setting using prescribing safety indicators (PSIs) and explore their implementation
and use in practice.
Methods: PSIs were identified and reviewed by the project team following a
literature review and a nominal group discussion. Pharmacists at 2 prison sites
deployed the PSIs using search protocols within their electronic health record. Preva-
lence rates and 95% confidence intervals (CIs) were generated for each indicator.
Semi-structured interviews with 20 prison healthcare staff across England and Wales
were conducted to explore the feasibility of deploying and using PSIs in prison
settings.
Results: Thirteen PSIs were successfully deployed mostly comprising drug–drug
interactions (n = 9). Five yielded elevated prevalence rates: use of anticholinergics if
aged ≥65 years (Site B: 25.8% [95%CI: 10.4–41.2%]), lack of antipsychotic monitor-
ing for >12 months (Site A: 39.1% [95%CI: 27.1–52.1%]; Site B: 28.6% [95%CI:
17.9–41.4%]), prolonged use of hypnotics (Site B: 46.3% [95%CI: 35.6–57.1%]),
antiplatelets prescribed with nonsteroidal anti-inflammatory drugs without gastroin-
testinal protection (Site A: 12.5% [95%CI: 0.0–35.4%]; Site B: 16.7% [95%CI:
0.4–64.1%]), and selective serotonin/norepinephrine reuptake inhibitors prescribed
with nonsteroidal anti-inflammatory drugs/antiplatelets without gastrointestinal pro-
tection (Site A: 39.6% [95%CI: 31.2–48.4%]; Site B: 33.3% [95%CI: 20.8–47.9%]).
Prison healthcare staff supported the use of PSIs and identified key considerations to
guide its successful implementation, including staff engagement and PSI 'champions'.
To respond to PSI searches, stakeholders suggested contextualised patient support
through intraprofessional collaboration.
Conclusion: We successfully implemented a suite of PSIs into 2 prisons, identifying
those with higher prevalence values as intervention targets. When appropriately
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resourced and integrated into staff workflow, PSI searches may support prescribing
safety in prisons.
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1 | INTRODUCTION
Adults in contact with the criminal justice system or residing in prisons
have greater mental and physical health needs compared to the gen-
eral population.1,2 It is acknowledged that patients make extensive
use of healthcare services during imprisonment,3,4 which presents an
opportunity to improve prisoner health. However, there is evidence of
varied practice in health-care delivery between prisons5,6 and the
need to focus on the quality and safety standards of prisoner care has
been emphasised in the UK.7,8
Prescribing practice is an important factor influencing the quality
and safety of prison healthcare alongside others such as staffing and
complications arising from an ageing prisoner population.8,9 For exam-
ple, there is evidence of potentially inappropriate prescribing in
prisons,9 and the chronic health needs of incarcerated patients may
also be overshadowed by issues related to the frequent misuse and
diversion of prescribed medication,10 with vigilance and risk manage-
ment processes important facets of prison prescribing.5
Prescribing safety indicators (PSIs) have been developed to
enhance the safety of prescribing.11–14 PSIs are statements describing
“a pattern of prescribing that could be hazardous and may put
patients at risk of harm”.11 Clinical trials and an interrupted time–
series evaluation have demonstrated that a pharmacist-led interven-
tion using PSIs to measure improvements in prescribing and medica-
tion monitoring safety in primary care significantly reduced the rates
of potentially hazardous prescribing.12,15
In contrast with their more extensive use and impact across pri-
mary and secondary care, there is limited evidence to date exploring
the development and application of PSIs to prison settings.16 Explor-
ing the prevalence of potentially hazardous prescribing, implementa-
tion and practical use of PSIs into prison electronic health records
(EHRs) can provide insight into ways to improve prescribing and moni-
toring practices at a national scale, as all 142 prisons in England and
Wales use the same EHR.17 This study, therefore, aimed to develop
and deploy a suite of PSIs into the EHRs of 2 UK prisons to determine
their prevalence, and to qualitatively explore their potential practical
use to improve medication safety.
2 | METHODS
Three study phases took place to examine the prevalence of PSIs in
2 large prisons and to explore their practical implementation and use
with stakeholders from England and Wales. The first phase involved
the identification and development of potential PSIs. The second was
the deployment of PSIs into 2 prison electronic health records to eval-
uate their frequency, and the third involved interviewing prison
healthcare staff to explore their views on accessing, using and
responding to PSI data, including any past experience of using PSI
data to improve prescribing and medication monitoring practices in
prisons.
Ethics approval for this study was granted by the National
Research Committee on 27 July 2018 (Reference 2018–211) for
Phase 1; the Health Regulatory Authority on 26 July 2019 (REC Ref-
erence 19/NW/0265) and National Research Committee on 22 May
2019 (Reference 2019–146) for Phases 2 and 3. Approvals were
obtained from prison Governors for PSI development and deployment
in the 2 study prisons.
What is already known about this subject
• Complex medication regimens are commonly prescribed
in prison settings, and therefore require careful manage-
ment to minimise the risk of adverse events.
• Prescribing safety indicators (PSIs) have been used to
enhance the safety of prescribing and monitoring, but
evidence for use in prisons is limited.
• Evaluating the implementation and practical use of PSIs
in prisons can provide insights to improve prescribing and
monitoring practices in this setting.
What this study adds
• We successfully deployed a tailored suite of 13 PSIs
across 2 prisons to help identify patients at risk of poten-
tially hazardous medication prescribing. Five out of 13
PSIs were associated with high prevalence between 12.5
and 46.3%.
• Unique contextual factors such as clinical coding and
patient issues were identified by stakeholders as key fac-
tors that would influence the successful implementation
and clinical response to PSI data.
• Our findings provide a framework for use of PSIs by
other secure environments as a platform for improve-
ment efforts, with the multidisciplinary team at its heart.
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2.1 | Phase 1: Identification and development of
candidate prescribing safety indicators
The identification and development of PSIs involved a 2-stage pro-
cess: (i) identification and development of PSIs by scoping relevant
published literature and using a nominal group discussion); and
(ii) reviewing/refining PSIs identified in stage 1 by the research team.
Existing PSIs developed for primary, secondary and mental
health-care settings were extracted from key PSI papers in the exis-
ting literature.14,18,19 In addition, a nominal group discussion was held
with prison healthcare and senior level professionals with at least
3 years' experience in UK prison settings, along with an interest in
medicines management/safety and/or experience in prescribing
safety and quality in prisons. The nominal question asked was, “what
medication-related errors/harms or examples of hazardous prescribing
are most likely to occur in the prison setting and what is their poten-
tial severity?” Panellists generated their contributions to the nominal
question and shared their responses in a round-robin format before
being discussed by the whole group.20,21 Pre-reading material con-
taining potential indicators from earlier studies identified from the lit-
erature search above were raised and discussed with the panel.14,18
Ideas generated during the discussion were prioritised by the group
resulting in a list of potential harms/errors associated with prescribing
and monitoring of medication (potential PSIs) alongside wider pre-
scribing safety challenges in prisons. A total of 11 generated ideas
with the potential to be PSIs were taken forward (Appendix 1). When
combined with the literature search findings, a total of 100 potential
PSIs were taken forward to the review stage by the research team
(Appendix 2).
Members of the research team (R.N.K., E.M.-M., P.B. and J.D.)
then independently reviewed the generated list of 100 potential PSIs
based on: (i) their clinical importance; and (ii) feasibility for deploy-
ment within UK prison settings (Table 1). The team included 1 prison
pharmacist member (J.D.) and 1 Chief Pharmacist (P.B.) involved in
prisons medicines management. R.N.K. and E.M.-M. are both practis-
ing clinical pharmacists in other sectors, and R.N.K. has expertise in
medicines safety and use of prescribing safety indicators.
Overall suitability for each indicator was then discussed face-to-
face amongst the research team using these 2 assessments together,
and indicators with higher clinical importance and feasibility were
selected by consensus to take forward to the deployment phase. Rea-
sons for exclusion included a lack of reliable clinical coding
(e.g. medical condition-related PSIs), rare prescribing events in prison
and PSIs specific to females (see below, PSI deployment sites were
male prisons). This process resulted in a total of 21 PSIs taken forward
to potential deployment (Appendix 3).
2.2 | Phase 2: Deployment of prescribing safety
indicators
Prison pharmacists (J.D. and A.O.) working in 2 male prison sites in
England and Wales collaborated with the research team to
operationalise and deploy 21 PSIs from Phase 1 by developing and
applying search protocols within the prison EHR (Table 2 shows char-
acteristics of the prison testing sites). These prisons were selected
based on convenience sampling and prior working relationships, and
the operationalisation process was supported by the EHR developer
who provided training in conducting the computer searches.
Prison pharmacists used an iterative test and feedback model to
validate the electronic PSI data. This involved optimising the search
for PSIs using EHRs and manually checking patient records to ensure
the results of the search were sensitive and specific in capturing data
of the PSIs. Clinical codes were utilised for laboratory value searches,
which are a thesaurus of clinical terms to record patient findings and
procedures in EHR.22 The team preferentially selected fully automated
PSIs for inclusion in the final list, due to resource constraints associ-
ated with manual screening of large numbers of patient records. The
test and feedback approach resulted in the exclusion of 8 further indi-
cators, due to: (i) the need for a combination of electronic and manual
searches (5 indicators); (ii) insufficient search capacity with the EHR
search tool (2 indicators); and (iii) insufficient use of the indicator
medication(s) in prisons (1 indicator).
Once the indicator search protocols were finalised and agreed,
final searches involving 13 PSIs were conducted in July 2020. Individ-
ual reports were generated before joining them together in a Venn
diagram fashion to establish all possible logical relations between the
reports.
Anonymised audit data extracted from prisoner health records
(for each PSI) included the number of patients affected by potential
PSIs (numerator), the number of patients in the at risk group (denomi-
nator) and the proportion (prevalence) affected (numerator/denomi-
nator  100) which was expressed as a percentage with
corresponding 95% confidence intervals.
2.3 | Phase 3: Semi-structured interviews to
explore practical implementation of prescribing safety
indicators
Semistructured telephone interviews were conducted with prison
healthcare staff to explore the feasibility of deploying and using PSIs
in prisons. This included barriers and enablers to accessing, viewing
and responding to PSI data in prisons. The goal was to generate rec-
ommendations for the deployment and application of PSIs to prison
TABLE 1 Criteria used to review potential prescribing safety
indicators based on their clinical importance (clinical impact and
frequency of prescribing in prisons) and feasibility (whether relevant
data needed for the indicator was routinely collected)
Clinical importance Feasibility score
1 Low High feasibility
2 Moderate Medium feasibility
3 High Low feasibility
4 Extreme
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settings. These topics were covered as part of a wider agenda to
explore the processes and factors influencing safe prescribing and
medication monitoring in prisons.5
Briefly, a flyer to publicise the study was emailed and circu-
lated via social media and shared professional networks across
England and Wales. Prison healthcare staff such as general practi-
tioners (GPs), psychiatrists, pharmacists, nurse prescribers and other
clinicians/managers with a minimum of 3 years prison-based expe-
rience and an interest in medicines management/safety were
invited to participate. Those who expressed interest in participating
were sent pre-reading material containing background information
about PSIs and their use. Written/verbal consent was obtained
from participants prior to conducting interview. The interview
schedule included questions related to challenges to medication
and prescribing safety and potential improvement strategies.5
Topics covered relating to PSIs and medication safety, and partici-
pants' experience of their deployment/impact in prisons are
included in Appendix 4 and are the focus of this paper.
Interviews took place from October 2019–July 2020, were digi-
tally audio-recorded and anonymised transcripts imported into NVivo
12 (QSR) for coding using inductive thematic analysis.23 Interviews
were independently coded by E.M.-M. and A.A., with a third author
(R.N.K.) reading 50% of transcripts and contributing to the develop-
ment of the final analytical framework that was agreed by these
3 authors.
3 | RESULTS
Thirteen fully automated PSIs were successfully deployed that con-
sisted of 9 drug–drug interaction, 2 drug monitoring, 1 drug-duration
and 1 drug–age indicators. Medications featuring in the PSIs included
3 mood stabilisers, 2 opioids, 2 antipsychotics, 2 antidepressants,
2 cardiovascular system agents, 1 anxiolytic, and 1 anticholinergic.
Table 3 shows the proportion of patients in both prisons triggered
by these 13 PSIs, including the number affected and the number of
patients in the at risk group. The prevalence of patients affected by a
PSI in Site A ranged between 0–39.6%, and in site B this ranged
between 0–46.3%. Five PSIs had 0% prevalence in both sites, 4 of
which were related to lithium.
Data across sites A and B revealed elevated prevalence
values for prescribing selective serotonin reuptake inhibitors (SSRI)/
selective norepinephrine reuptake inhibitors (SNRI) with nonsteroidal
anti-inflammatory drugs (NSAIDs) or antiplatelets with no gastrointes-
tinal (GI) protection (A: 39.6% (95%CI: 31.2–48.4); B: 33.3% (95%
CI:20.8–47.9)), prescribing antiplatelets with NSAIDs without GI pro-
tection (12.5% (95%CI: 0.0–28.7); 16.7% (95%CI:0.4–64.1)), and pre-
scribing antipsychotics for at least 12 months without monitoring
blood glucose, weight or lipid profile within the previous year
(39.1% (95%CI:27.1–52.1); 28.6% (95%CI:17.9–41.4)). Site B also
had high prevalence values for patients who were prescribed
benzodiazepines, Z-drugs or sedating antihistamines for >1 month
(46.3% [95%CI:35.6–57.1]) and prescribing a medication with
medium/high anticholinergic activity to a patient aged ≥65 years
(25.8% [95%CI:10.4–41.2]). Zero prevalence values were reported for
5 indicators from both sites, of which 4 were related to lithium.
3.1 | Practical implementation and utility of
prescribing safety indicators in prisons (interviews)
A total of 20 prison healthcare staff were interviewed to explore the
practical use of PSI data in prisons. This included 10 pharmacists,
6 GPs, 3 psychiatrists and 1 nurse. Of these, 9 participants (5 pharma-
cists, 3 GPs and 1 psychiatrist) reported to have some existing experi-
ence with PSIs, which involved prescribing quality/safety audits and
clinical reports.
Four key themes emerged from the data: (i) accessing PSIs;
(ii) usability of PSIs; (iii) reviewing and reporting PSIs; and
(iv) responding to PSIs.
3.1.1 | Accessing PSIs
To optimise searching for PSIs using the EHR, respondents with direct
experience working on PSIs recognised the need for accurate coding
of patient data related to diagnoses, prescribing and monitoring. Par-
ticipants reported a number of barriers related to inconsistencies in
data-entry using clinical codes into the her, which made conducting
PSI searches complex. Some reported that clinical codes were at times
TABLE 2 Prison prescribing safety indicator testing site characteristics
Prison characteristics Site A Site B
Category C (with remand and men convicted of sexual offences [MCOSO] function) B (training prison with category A unit)
Sex Male Male
Age range General & MCOSO = 21+ y
Remand = youth offenders (18–21 y) and adults
21+ y
Healthcare wings One assisted mental health community Inpatient unit
Category B are prisons that are either local or training prisons. Training prisons hold long-term and high-security prisoners who are convicted of serious
offences such as murder or rape, but are considered to be of lower risk. Category C are prisons that are training and resettlement prisons, which provide
prisoners with the opportunity to develop their own skills in order to resettle back into the community on release. Prisoners in Category C are usually
convicted with minor offences and shorter lengths of stay. Most prisoners are in Category C.42
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entered either incorrectly, were not documented, or were not used in
certain specialties such as psychiatry. In some cases, the variation in
clinical coding was as a result of different professions coding differ-
ently. Participants recognised that more training is needed to use the
EHR to its full potential.
“They're (GPs) generally very good at [clinical] codes
because it's a system they use in primary care. The psy-
chiatrists use ICD-10, we use completely different sys-
tems to code what we diagnose. We don't really use the
[clinical] code system or in psychiatry in the community
here.” (Interview 7, Psychiatrist).
Variation in the use of the EHR between prisons affected the per-
ceived feasibility of implementing PSI searches into practice. If clinical
codes were not entered correctly, searching for specific patients
proved to be difficult and time-consuming.
Participants felt that the EHR could be better utilised to support
PSI searches if an interface/data sharing between GP and prison set-
tings occurred to ensure continuity in patient care when prisoners
were released.
“So [EHR], it has no interface with GPs and the outside …
I think the drug-seeking behaviour would be curbed and I
think the documentation and continuity would be so
much more accurate and easier. And it would also sort
the problem out of, if this audit was run, it pointed out
that this PSI has not been met, that information would
transfer to wherever the prisoner is going.” (Interview
2, Pharmacist).
3.1.2 | Usability of PSIs
A number of factors influenced the applicability and usability of PSIs
in practice. This included staff motivation and engagement to use
PSIs, their time and capacity, the type of prison and service offered
and who would have responsibility for generating this data.
Recognising the potential for increased workload associated with con-
ducting a PSI search, the majority of participants who were mainly
pharmacists or GPs emphasised the need to delegate a member of
staff to generate PSI reports. However, not all prisons were reported
to have regular staff or an on-site pharmacy service and some men-
tioned relying on locum GPs to provide routine clinical services. The
majority of participants stated that employed pharmacists or nurses
would be ideal to conduct regular PSI searches and to also support
continuity of patient care. Those with prior experience of using pre-
scribing safety/quality indicators reported devising methods to over-
come staffing issues such as using central reporting teams and EHR
data analysts to search and submit PSI reports.
“Because we're doing this centrally, and sending back
something that looks quite pretty to the teams, then I
think it's used more because we send something out as an
end product, in terms of graphs, and something with
dashboards, something looking nice.” (Interview
12, Pharmacist).
Many participants described the importance of engaging
healthcare staff to use PSIs by explaining their rationale for use and
how the reports may be used to their advantage. This included the
benefits at an organisational level, such as using PSI reports to con-
duct audits, monitor the implementation of new guidance, and
improve prescribing and monitoring practices. One participant com-
mented that staff may be more inclined to adopt PSIs if the benefits
outweighed the workload burden.
“As long as they believe this is a real risk and by doing
the thing that they need to do reduces that risk, that pro-
vides benefit then I think they would take it on.” (Inter-
view 3, Pharmacist).
A couple of participants stated that prison management consid-
ered nonpatient facing work to be unproductive and therefore PSI
activity would probably be deemed as noncommissioned “clinical gov-
ernance work” (Interview 17, GP). One participant commented that
embedding this task into service specifications and job roles could
help resolve this issue.
3.1.3 | Reviewing and reporting PSIs
Participants with experience of PSIs described the need to check
the validity of the search and have the ability to interpret them
accurately. This was the case when administrative staff were
tasked to conduct a patient search and were unable to clinically
interpret the results.
“So I think our [EHR] sort of user experts have looked at
it, but they don't have the clinical knowledge to interpret
… so they don't know what they can and can't tweak
within the kind of the clinical aspects of the report; so
there's not been that joint bit of work which would be
useful I think.” (Interview 4, Pharmacist).
Participants also reported the need to manually check that
there is indeed a real risk to the patient identified as being
affected by a PSI—filtering patients with a theoretical risk that is
acceptable in clinical practice was 1 example discussed by this
participant.
“So say we had 19 patients who are on Bisoprolol for
asthma or COPD [chronic obstructive pulmonary disease]
but it's all cool, it's all fine, the benefits outweigh the risks,
it's okay. They'll always remain on those indicators at the
moment” (Interview 14, Pharmacist).
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In addition to engaging healthcare staff to use PSIs, 1 pharmacist
stated that GPs were more likely to initiate action plans if reports
were presented in an accurate and understandable format, which
would help them save time. Many participants also mentioned the
importance of engaging healthcare staff to utilise PSIs by delegating a
PSI-champion to drive it forward.
“You do generally need somebody who's interested in
it [PSI reports]. If it was a huge safety concern … I
think they [GPs] would generally do it. But if it was
something like, let's look at all patients on something,
they all need reviewing, then that might take a bit of
… getting somebody engaged to do it. And you find
different sites react in different ways.” (Interview
14, Pharmacist).
3.1.4 | Responding to PSIs
A common theme to addressing PSI reports was intraprofessional
collaboration. Many healthcare staff reported having regular medi-
cation management meetings to promote a safer prescribing
culture and address challenges to prescribing in prisons. This
included difficulties in approaching aggressive or verbally abusive
patients and the need to devise a consistent intraprofessional
approach to communicating with patients if the prescriber changes
or discontinues certain medications. A few participants commented
that the unique nature of a prison settings resulted in prescribers
having more responsibility and accountability for patients. Assessing
patients in a holistic manner based on their clinical profile and con-
text was reported to influence how healthcare staff may choose to
respond to PSIs, such as the patient's willingness to change medi-
cation, risk of suicide/self-harm/medication diversion and any
potential drug–drug interaction of prescribed medicines with illicit
drugs.
“We provide the teams, on a monthly basis, with a medi-
cines optimisation dashboard, and the patient safety indi-
cators only form one strand of that dashboard … we also
track prescribing trends of abusable medicines, formulary
compliance, numbers of medicines, reconciliations, that
have completed, there's a few substance misuse measures
in there, a few antibiotic stewardship measures” (Inter-
view 12, Pharmacist).
By devising methods through intraprofessional collaboration to
improve prescribing and monitoring, participants commented that PSI
reports could also be used in patient consultations to make patients
aware of the rationale for medication changes.
“It's useful to show patients, isn't it? To say actually look,
this has flagged up. I'm not making it up. I'm not having a
bad day.” (Interview 1, General Practitioner).
Ultimately, the implementation of PSIs in prison settings was per-
ceived by stakeholders to rely on a series of stages that supported the
development of a report with action plans to address the results from
the PSI search. This has been summarised in Figure 1.
4 | DISCUSSION
We have successfully deployed a suite of PSIs in prisons to examine
their prevalence whilst also exploring their practical utilisation in order
to understand their optimal deployment and use. Our findings high-
light that particular PSIs may be common and pose an important
threat to patient safety in this setting, making them a potential
improvement target. Alongside this we identify key considerations
and strategies supporting successful implementation of PSIs, many of
which reflect characteristics unique to the prison environment and its
patient population. We envisage that use of these PSIs and our
F IGURE 1 Processes involved for the implementation of prescribing safety indicators in prison settings
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interview findings will support prison health-care staff to understand
and take mitigating action against potentially hazardous prescribing in
their care settings, whilst also providing opportunities for the develop-
ment or adoption of new medication safety improvement interven-
tions. By focusing on high risk prescribing and harnessing the
potential of EHRs, our work supports national and international
health-care strategy goals to improve medication safety across care
settings.24,25
Our findings reveal that the indicators SSRI/SNRIs with NSAIDs/
antiplatelets without GI protection, antipsychotics prescribed for at
least 1 year without monitoring blood glucose, weight or lipid profile
within the previous year, and antiplatelets prescribed with NSAIDs
without GI protection were commonly reported across both study
sites. Studies show that patients in prisons have a raised prevalence
of mental disorders1,26 and psychotropic medication prescribing with
47.9% of women and 16.9% of men prescribed at least 1 psychotropic
medicine in English prisons.9 This may later result in further health
complications due to the increased risk of cardiovascular disease and
cardiovascular-related mortality in patients with severe mental ill-
ness.27 In addition, the prescribing of hypnotics for >1 month, and
anticholinergics with medium or high activity to patients older than
65 years were also found to be common in Site B. With the number
of older incarcerated patients increasing28 the numbers potentially
exposed to anticholinergic medications and heightened bleeding risk
may also rise. For example, recent studies reveal that strong anticho-
linergic medicines are associated with an increased risk of developing
dementia29 and that advancing age is an established risk factor for GI
bleed when prescribed other medications such as SSRIs/SNRIs, which
are known to increase this risk.30,31 The variation in the prevalence of
some indicators between our study sites reveals that prescribing pat-
terns and hence the level of risk from PSIs in prisons may vary, as it
does in general practice. Indeed, studies from primary care also reveal
variability in high-risk prescribing between practices.32 There may be
opportunities to standardise prescribing practice in prisons, whilst also
taking into consideration local issues for targeted practice interven-
tions. Whilst prisoner turnover can be high,33 it is important that ade-
quate medication monitoring is carried out. The opportunity to treat
patients in prison settings and continue to care for their health out-
side can be obstructed due to the lack of system interoperability with
GP practices. Moreover, prisons that rely heavily on locum staff may
result in additional medication monitoring barriers due to the lack of
prescriber continuity.5
Conversely, the prescribing of SSRI/SNRIs with novel oral antico-
agulants or warfarin, and the coprescribing of opioids with either
methadone/buprenorphine or gabapentin/pregabalin was less com-
monly observed across both study sites. The apparent low prevalence
of coprescribing gabapentinoids in both sites may reflect increased
awareness nationally among prescribers of the risk of diversion of
these medicines as currency to obtain illicit drugs in prison30 as well
as elevated reports of drug-related deaths among prisoners from opi-
oids and gabapentinoids.34
Our study revealed key practical considerations associated with
running and responding to PSI searches in prison settings. Whilst we
were able to operationalise and deploy 13 fully automated searches,
which may reduce workload associated with creating indicators
locally, our findings highlight that these PSI searches depend upon
accurate data entry into the EHR and interoperability with primary
and secondary care settings. Other key considerations included staff
time, capacity and engagement to search PSIs, the ability to validate
and interpret results from a PSI search and supporting methods of
responding to PSI searches through intraprofessional collaboration. As
with our study, others have identified the need for a designated staff
member to act as the change agent when responding to errors through
intraprofessional collaboration.35,36 Within the PINCER trial, the phar-
macist took a lead with this role, and received training and spent time
establishing working relationships with general practice staff, which
helped them become familiar with contextual information to provide
implementation support.12 Moreover, conducting a PSI search would
need to be viewed as an important task that would also need to be
sustained as part of normal work practices. Healthcare staff in our
study emphasised the need to engage staff to use PSIs by rationalising
the benefit of using PSIs in their practice, which has been reported
elsewhere.12,35,37 Whilst our findings reveal apparent similarities
between prison health care and other settings in the important facets
supporting successful PSI delivery processes, they also identify chal-
lenges more unique to the secure environment and its patients. These
include issues relating to limitation in which PSIs may be possible to
search due to incomplete clinical coding in records; consistent avail-
ability of clinical staff to lead PSI searches and respond to PSI data;
and taking action to address PSI data in a way that holistically reflects
patient-prisoner characteristics.
Our study supports wider evidence5,38,39 that medication man-
agement in prisons may be fragmented. Continuity of care is affected
both during incarceration (e.g. varying staff, turnover) and the transfer
of patients into/from prisons. We have provided suggestions for how
improvement may be realised using PSIs, with key considerations that
reflect the unique prison setting. Utilising the prison EHR as the host
of PSI searches may also enable rapid and consistent PSI searches at
scale. There is therefore now the opportunity for health-care leaders
and researchers to conduct further work to upscale this project and
widen automated access to this data (for example, as part of a national
medication safety dashboard)40 alongside using it as a basis for reme-
dial intervention development, which will address key medicines
safety improvement goals (for example concerning safety measure-
ment).24,25,40
4.1 | Study strengths and limitations
Our study has the following limitations. It was restricted to adult
male prisons, which meant we that were unable to explore indica-
tors and risk profiles specific to women's prisons and young
offender institutions. We chose to exclude women's prisons to be
broadly generalisable, as female prisoners make up <5% of the
overall prison population.41 Nonetheless, our indicators could
potentially be applied to women prisons. We were unable to deploy
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PSIs that required manual searching due to resource constraints
(although we do present these in the Appendix). In addition, it was
not possible to interview prisoners or prison IT staff, which may
have been useful when exploring how to optimise and address PSI
search results.
A key strength of our study is that we explored in-depth the prac-
ticality of PSI implementation and use in clinical practice with a range
of stakeholders that included those with prior experience of PSI
implementation in this setting. Despite restricting deployment of the
PSIs to 2 large prisons, we are confident that our pragmatic design
can be replicated to measure the prevalence of PSIs in other secure
environments.
5 | CONCLUSION
Prescribing safety indicators were successfully implemented into the
EHR of 2 large prisons, with a subgroup of indicators associated with
elevated prevalence targeted for intervention. We also identified
important factors underpinning the key steps to successfully
implementing and using PSI data in prisons, some of which reflected
this unique environment and its patient population. These findings
form a foundation from which others may deploy their own PSI suites
to facilitate prescribing safety improvement and address international
safety priorities.
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APPENDIX A
APPENDIX B
TABLE A1 Ideas with the potential to be prescribing safety indicators generated from the nominal group discussion (NGD)
Grouped themes Ideas generated
Specific central nervous system
groups
Methadone prescribed with QT-prolonging drugs without electrocardiogram
Coprescribed opioid with methadone
Methadone prescribed with gabapentin/pregabalin
Prescribing opioid drugs with high dose of buprenorphine
No methadone dose reduction after stopping tuberculosis medicines
Gabapentinoids prescribed in substance misusers
Medicines use Prescribing sodium valproate in women without contraception/consent issues
Antipsychotic load British National Formulary percentage maximum dose exceeded
Nicotine replacement therapy patches and concurrent use of vaping, and over 12 wk of nicotine replacement
therapy prescribed
Clozapine prescribed with nicotine replacement therapy
Practitioner behaviour Dual antiplatelet therapy that is not stopped when appropriate
TABLE A2 Prescribing safety indicators generated from nominal group discussion and literature review which were reviewed by members of
the research team
GROUP INDICATOR ASSOCIATED RISK
1 OPIOID Methadone prescribed with QT-prolonging drugs
without electrocardiogram
Risk of QT prolongation that can lead to potentially
fatal torsade de pointes arrhythmia
2 OPIOID Coprescribed opioid with methadone Risk of sedation, respiratory depression
3 OPIOID Coprescribed methadone with gabapentin/pregabalin Risk of sedation, respiratory depression
4 OPIOID Prescribing opioid based analgesia with high dose
buprenorphine
Risk of sedation, respiratory depression
5 OPIOID No methadone dose reduction after stopping
tuberculosis medicines
Increased risk of methadone overdose
6 OPIOID Opioid patch prescription Increased risk of abuse/diversion
7 OPIOID Tramadol prescribed with opioids in wrong preparation
(24 h/12 h)
Toxicity or subtherapeutic dose
8 OPIOID Tramadol prescribed concomitantly with a monoamine
oxidase inhibitor
Increased risk of serotonin syndrome
9 OPIOID Tramadol prescribed concomitantly with antiepileptics Increased risk of seizures in patients with uncontrolled
epilepsy
10 ANTI-EPILEPTICS Gabapentinoids prescribed in substance misusers Increased risk of sedation, respiratory depression
11 ANTI-EPILEPTICS Prescribing sodium valproate in women of child-bearing
potential without contraception/consent issues
Increases the risk of birth defects
12 Nicotine replacement
therapy (NRT)
NRT—patches and concurrent use of vaping + over
12 wk of NRT
Risk of nicotine overdose
13 ANTIPSYCHOTICS Clozapine with NRT Dose adjustment may be required if smoking
stopped/started during treatment
14 ANTIPSYCHOTICS Clozapine dose not adjusted or omitted in a patient with
a clozapine concentration above therapeutic range
600 μg/L
Increased risk of adverse effects
(Continues)
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TABLE A2 (Continued)
GROUP INDICATOR ASSOCIATED RISK
15 ANTIPSYCHOTICS Clozapine prescribed without monitoring lipid profile
and weight every 3 mo for the first year, then yearly.
Increased risk of adverse effects—cardiovascular
disease
16 ANTIPSYCHOTICS Clozapine prescribed without monitoring fasting blood
glucose tested at baseline, after 1 mo treatment, then
every 6 mo
Increased risk of adverse effects—elevated blood
sugar
17 ANTIPSYCHOTICS Clozapine prescribed without monitoring blood pressure
(sitting and standing) at baseline, after 1, 2, 3 and
6 mo and annually
Increased risk of adverse effects—cardiovascular
disease, tachycardia
18 ANTIPSYCHOTICS Clozapine prescribed without monitoring leucocyte and
differential blood counts weekly for 18 wk then
fortnightly for up to 1 y, and then monthly
Risk of potentially fatal agranulocytosis,
contraindicated with past medical history of
agranulocytosis and neutropenia
19 ANTIPSYCHOTICS Clozapine prescribed to a patient with leukocyte count
<3000/μL or if absolute neutrophil count <1500/μL
Increased risk of neutropenia
Risk of agranulocytosis
20 ANTIPSYCHOTICS Prescribing clozapine with anticholinergic medicine Risk of constipation and potentially fatal risk of
intestinal obstruction, faecal impactioncand
paralytic ileus
21 ANTIPSYCHOTICS Prescribing antipsychotics for patients with prolonged
QTc interval
Risk of potentially fatal torsade de pointes arrhythmia
22 ANTIPSYCHOTICS Prescribing antipsychotics without monitoring full blood
count (FBC), urea and electrolytes (U&Es), prolactin,
liver function tests (LFTs), glucose, weight, or lipid
profile annually
FBC: risk of blood dyscrasias
U&Es: to avoid overdose and electrolyte abnormalities
than can increase the risk of QTc prolongation
Prolactin: risk of hyperprolactinaemia
LFTs: risk of increasing liver enzymes and hepatic
disorders glucose, weight, or lipid profile: risk of
metabolic adverse effects
23 ANTIPSYCHOTICS Prescribing antipsychotics without monitoring prolactin
at baseline and 6 mo after starting therapy
Risk of hyperprolactinaemia
24 ANTIPSYCHOTICS Prescribing antipsychotics without monitoring glucose,
weight, lipid profile at baseline and 3 mo after starting
therapy
Risk of metabolic adverse effects
25 ANTIPSYCHOTICS Antipsychotic load British National Formulary (BNF)
percentage max dose exceeded
Risk of toxicity
26 ANTIPSYCHOTICS Prescribing antipsychotic with QT prolonging drugs
(antiarrhythmic with QT interval-prolonging
properties [e.g. amiodarone, disopyramide, flecainide,
and sotalol], macrolides, azole antifungal,
moxifloxacin, citalopram and escitalopram)
Risk of QT prolongation that can lead to potentially
fatal torsade de pointes arrhythmia)
27 ANTIPSYCHOTICS Zuclopenthixol acetate prescribed in combination with
regular antipsychotics
Risk of QT prolongation that can lead to potentially
fatal torsade de pointes arrhythmia
28 ANTIPSYCHOTICS Prescribing high dose antipsychotics (above BNF 100%
maximum)
Risk of anticholinergic and extrapyramidal effects
29 ANTIPSYCHOTICS Lithium dose not adjusted or omitted in a patient with a
lithium concentration above the therapeutic range
(>1.0 mmol/L)
Risk of lithium toxicity
30 ANTIPSYCHOTICS Lithium prescribed in conjunction with newly prescribed
nonsteroidal anti-inflammatory drugs (NSAIDs)
without dose adjustment or increased monitoring
Increased risk of toxicity
31 ANXIOLYTICS Prescribing benzodiazepines or Z-drugs for patients
aged ≥ 65 y
Increased risk of falling and fracture
32 ANXIOLYTICS Benzodiazepine or benzodiazepine-like drug prescribed
to a patient with chronic obstructive pulmonary
disease
Risk of respiratory depression
33 ANXIOLYTICS Benzodiazepines prescribed long term (i.e. >2–4 wk)
Benzodiazepine-like drugs (e.g. zopiclone) prescribed
long term (i.e. >2–4 wk)
Risk of dependence and withdrawal reactions
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TABLE A2 (Continued)
GROUP INDICATOR ASSOCIATED RISK
34
35 ANXIOLYTICS Prescribing benzodiazepine, Z-drugs or sedating
antihistamine for >1 mo
Risk of prolonged sedation, confusion, impaired
balance, falls
36 ANXIOLYTICS Benzodiazepine or benzodiazepine-like drug prescribed
during pregnancy
Risk of neonatal withdrawal symptoms
37 ANXIOLYTICS Prescribing 2 benzodiazepines or Z-drugs concurrently Increased risk of falling and fracture
38 ANXIOLYTICS Coprescribing benzodiazepines or Z-drugs with strong
CYP3A4 inhibitor
Increases exposure, which results in reduced
psychomotor functioning and prolonged sedation
39 ANTIDEPRESSANTS Prescribing tricyclic antidepressants for patients aged
≥65 y except in low dose for neuropathic pain
Highly anticholinergic, sedating, and cause orthostatic
hypotension
Age
40 ANTIDEPRESSANTS Prescribing bupropion for patients aged ≥65 y May lower seizure threshold
41 ANTIDEPRESSANTS Tricyclic antidepressant prescribed at the same time as a
monoamine oxidase inhibitor (MAOi)
Increased risk of serotonin syndrome
42 ANTIDEPRESSANTS Selective serotonin reuptake inhibitor (SSRI) prescribed
concomitantly with tramadol
Increased risk of serotonin syndrome
43 ANTIDEPRESSANTS SSRI prescribed concomitantly with/without appropriate
prophylaxis with antisecretory drugs or mucosal
aspirin protectant
Increased risk of gastrointestinal bleeding
44 ANTIDEPRESSANTS Citalopram prescribed concomitantly with other QT-
prolonging drugs
Increased risk of arrhythmias
45 ANTIDEPRESSANTS Prescribing SSRI/selective norepinephrine reuptake
inhibitors (SNRIs) with NSAID or aspirin with no
gastrointestinal protection
Increased risk of gastrointestinal bleeding
46 ANTIDEPRESSANTS Prescribing SSRI/SNRIs with novel anticoagulants or
warfarin
Increased risk of bleeding
47 ANTIDEPRESSANTS Coprescribing SSRI/SNRIs with linezolid Increased risk of serotonin syndrome
48 ANTIDEPRESSANTS Coprescribing SSRI with tramadol Increased risk of serotonin syndrome
49 ANTIDEPRESSANTS Coprescribing MAOi with amphetamine and its
derivatives
Risk of potentially fatal hypertensive crisis and/or
serotonin syndrome
50 ANTIDEPRESSANTS Coprescribing MAOi with opioids Increased risk of serotonin syndrome, and opioids
toxicity
51 ANTIDEPRESSANTS Coprescribing MAOi with levodopa Risk of serious and potentially life-threatening
hypertensive reaction
52 ANTIDEPRESSANTS Coprescribing MAOi with carbamazepine Increased risk of serotonin syndrome
53 ANTIDEPRESSANTS Coprescribing MAOi with sumatriptan Risk of serotonin syndrome, MAOIs increases the
exposure to sumatriptan
54 ANTIDEPRESSANTS Coprescribing MAOi for pregnant women Increased risk of neonatal malformations
55 ANTIDEPRESSANTS Coprescribing citalopram, escitalopram, clomipramine or
venlafaxine with QT-prolonging drugs
Increased risk of arrhythmias
56 ANTIDEPRESSANTS Coprescribing fluvoxamine with theophylline Risk of theophylline toxicity
57 ANTIDEPRESSANTS Coprescribing trazodone with hepatitis C virus antiviral Cause QT prolongation that can lead to potentially
fatal torsade de pointes arrhythmia
58 ANTIDEPRESSANTS Coprescribing antidepressants with selegiline Increased risk of serotonin syndrome
59 MOOD STABILISERS Coprescribing carbamazepine with strong CYP3A4
inhibitor
Risk of carbamazepine toxicity which can cause
dizziness, diplopia, ataxia and mental confusion
60 MOOD STABILISERS Coprescribing carbamazepine with oral or intravaginal
contraceptives, patches or pure progestogen pills
Risk of failure of contraception and risk of foetal
malformation
61 MOOD STABILISERS Coprescribing carbamazepine with warfarin/direct oral
anticoagulants
Risk of reducing anticoagulation effect which can
cause blood clots
62 MOOD STABILISERS Coprescribing carbamazepine with clozapine
(Continues)
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TABLE A2 (Continued)
GROUP INDICATOR ASSOCIATED RISK
Risk of reducing clozapine concentration, risk of
blood dyscrasias and risk of fatal pancytopenia or
neuroleptic malignant syndrome
63 MOOD STABILISERS Coprescribing carbamazepine for pregnant women Increases the risk of neural tube defects
64 MOOD STABILISERS Coprescribing lithium with angiotensin converting
enzyme inhibitor/angiotensin receptor blocker
Risk of lithium toxicity which can cause tremor,
dysarthria, ataxia and confusion
65 MOOD STABILISERS Coprescribing lithium with diuretics Risk of lithium toxicity which can cause tremor,
dysarthria, ataxia and confusion, and risk of
hypokalaemia which increase the risk of torsade de
pointes
66 MOOD STABILISERS Coprescribing lithium with NSAID Risk of lithium toxicity which can cause tremor,
dysarthria, ataxia and confusion
67 MOOD STABILISERS Coprescribing valproic acid with lamotrigine Risk of increasing lamotrigine concentrations and
cause sedation, tremor, ataxia, fatigue and rash
68 MOOD STABILISERS Coprescribing valproic acid with carbapenems Dramatically decreases the serum concentration of
valproate—reduced concentration of valproic acid
may lead to increased risk of clinical deterioration,
e.g. seizures, mental illness)
69 MOOD STABILISERS Women of childbearing potential prescribed valproate Risk of congenital malformations
70 MOOD STABILISERS Prescribing lamotrigine with hormonal contraceptive or
combination pills
Risk of failure of contraception
71 MOOD STABILISERS Prescribing carbamazepine without monitoring U&E and
plasma levels of carbamazepine every 6 mo
Risk of carbamazepine toxicity which can cause
dizziness, diplopia, ataxia and mental confusion
72 MOOD STABILISERS Lithium preparation not prescribed by brand Increased risk of toxicity or therapeutic failure




Prescribing clonidine with propranolol Risk of bradycardia and hypotension
75 ADHD Methylphenidate modified-release not prescribed by
brand
Increased risk of toxicity or therapeutic failure
76 ADHD Prescribing any ADHD medication without monitoring
heart rate, blood pressure, height and weight at
baseline
Risk of raised heart rate and blood pressure, and risk
of growth suppression
77 ADHD Prescribing any ADHD medication without monitoring
heart rate and blood pressure every 6 mo
Risk of raised heart rate and blood pressure
78 ANTIDEMENTIA Prescribing 2 anticholinesterase inhibitors Risk of accumulation of side effects
79 ANTICHOLINERGICS Prescribing 2 anticholinergics with at least 1 of them
strong or moderate
Increased risk of cognitive impairment, falls and all-
cause mortality in older people
80 Cardiovascular system
(CVS)
Dual antiplatelet therapy that is then not stopped Increased risk of bleeding
81 CVS Continuing of deep vein thrombosis treatment because
no plan in place
Increased risk of bleeding
82 CVS Digoxin prescribed at a dose >125 mg daily to a patient
with renal impairment
Increased risk of digoxin toxicity
83 CVS Warfarin prescribed with any antibiotic without
international normalised ratio monitoring within 5 d
Increased risk of bleeding
84 CVS Warfarin prescribed concomitantly with a NSAID Increased risk of bleeding
85 CVS Clopidogrel prescribed to a patient concomitantly with a
NSAID
Increased risk of bleeding
86 CVS Verapamil prescribed with β- blocker Increased risk of heart block, bradycardia
87 CVS Low-molecular-weight heparin omitted to be prescribed
for prophylaxis
Increased risk of thrombosis
88 ENDOCRINE Increased risk of lactic acidosis
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GROUP INDICATOR ASSOCIATED RISK
Metformin prescribed to a patient with estimated
glomerular filtration rate <30 mL min1 (1.73 m)2
89 ENDOCRINE Weekly dose of an oral bisphosphonate prescribed daily Risk of hypocalcaemia
90 INFECTION Penicillin prescribed to a patient with a history of
penicillin allergy
Risk of hypersensitivity reactions
91 INFECTION Penicillin-containing compound prescribed to a
penicillin-allergic patient without reasoning (e.g. a mild
or nonallergy such as diarrhoea or vomiting entered as
an allergy where the indication for penicillin is
compelling)
Risk of hypersensitivity reactions
92 INFECTION Gentamicin prescribed to a patient with renal
impairment without dose adjustment
Increased risk of toxicity
93 INFECTION Vancomycin prescribed intravenously to a patient with
renal impairment without dose adjustment
Increased risk of toxicity
94 INFECTION Quinolone prescribed to a patient who is also receiving
theophylline
Possible increased risk of convulsions
95 IMMUNOSPRESSION Oral methotrexate prescribed to a patient with an
inappropriate frequency
Increased risk of toxicity
96 IMMUNOSPRESSION Methotrexate prescribed without folic acid Increased risk of mucosal and gastrointestinal side-
effects and hepatotoxicity
97 IMMUNOSPRESSION Coprescribing of methotrexate 2.5 and 10 mg Increased risk of dosing error and toxicity
98 IMMUNOSPRESSION Prescription of methotrexate without record of LFT in
previous 3 mo
Risk of hepatic dysfunction undetected
99 IMMUNOSPRESSION Prescription of methotrexate without record of FBC in
previous 3 mo
Blood dyscrasias reported, including fatalities and risk
of going undetected
100 ANALGESIA More than 1 paracetamol-containing product prescribed
to a patient at a time
Maximal dose exceeded, risk of liver toxicity
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APPENDIX C
TABLE A3 Final list of prescribing safety indicators taken forward to deploy into prison electronic health records
INDICATOR Duration
Patients at risk of prescribing
safety indicator (denominator)
Patients receiving prescribing
safety indicator (numerator) ASSOCIATED RISK
Coprescribed opioid with
methadone/buprenorphine
6 mo Prescribed any opioid or
methadone during the 6-
month period
Prescribed any opioid and
concurrently prescribed
methadone during the 6-mo
period









opioid during the 6-mo
period
Risk of sedation, respiratory
depression, mortality
Antipsychotic prescribed for
at least 12 months without
monitoring glucose, weight
or lipid profile within the
previous year
13 mo Prescribed any antipsychotic in
month 1 and again in month
13
Have not had glucose, weight
and/or lipid profile test
within the screening 13-mo
period




6 mo Prescribed any antipsychotic
during the 6-month period
Prescribed any QT-prolonging
drug during the 6-mo period
Risk of QT prolongation that






6 mo Prescribed >1 regular
antipsychotic other than




clozapine for >2 mo during
the 6-mo period (any 3 mo
during 6-mo window)






6 mo Prescribed lithium during the 6-
month period
Prescribed NSAID during the
6-mo period, and not in the
previous 3-mo period
Increased risk of toxicity
Prescribing benzodiazepine,
Z-drugs or sedating
antihistamine for >1 month
3 mo Prescribed benzodiazepine, Z-
drug or sedating




antihistamine for >1 mo
during the 3-mo period (any 2
mo during 3-mo period)





6 mo Prescribed benzodiazepines or
Z-drug during the quarter
Prescribed benzodiazepines and
concurrently prescribed Z-
drug during the quarter





or trazadone with QT-
prolonging drugs










during the 6-mo period
Risk of QT prolongation that




NSAID or antiplatelet with
no gastrointestinal
protection
6 mo Prescribed SSRI/SNRI and
concurrently prescribed an
NSAID or antiplatelet during
the 6-month period
Not prescribed gastroprotection





6 mo Prescribed SSRI, SNRI, warfarin
or DOAC during the 6-month
period
Prescribed SSRI or SNRI and
concurrently prescribed
warfarin or DOAC during the
6-mo period
Increased risk of bleeding
Prescribing lithium with
ACEi/ARB
6 mo Prescribed lithium or ACEi/ARB
during the 6-month period
Prescribed lithium and
concurrently prescribed
ACEi/ARB during the 6-
Risk of lithium toxicity which
can cause tremor, dysarthria,
ataxia and confusion
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APPENDIX D
Interview Schedule
Prescribing Safety Indicators and medication safety.
Have a look at the prescribing safety indicators (PSIs) examples
we sent to you, to help you understand the purpose and use of
patient safety indicators for safer prescribing, which is to help identify
patients who are at risk of harm. We would like you to think about
those statements, and using them in practice.
For the following PSIs:
1. Would you want to access PSI data like this? How would you want
to access it?
2. How would you go about reviewing it/responding to the data?
3. What kind of impact do you think this would have—on staff, on
prescribing, on workload on patient safety?
4. What would prevent you from using PSIs like this in your prison?
5. What would help/support you to use PSI like this in your prison?
TABLE A3 (Continued)
INDICATOR Duration
Patients at risk of prescribing
safety indicator (denominator)
Patients receiving prescribing
safety indicator (numerator) ASSOCIATED RISK
Prescribing lithium with
diuretics
6 mo Prescribed lithium or a diuretic
during the 6-month period
Prescribed lithium and
concurrently prescribed
diuretic during the 6-mo
period
Risk of lithium toxicity, which
can cause tremor, dysarthria,
ataxia and confusion, and risk
of hypokalaemia, which
increase the risk of torsade
de pointes
Lithium prescribed for at least
6 months without
monitoring U&E or thyroid
function within the last
6 months
6 mo Lithium prescribed in period
6 months before screening
period and in 6 month
screening period
Have not had U&E and/or
thyroid function testing
during the 6 mo screening
period
U&E: risk of lithium toxicity and
renal impairment
Thyroid: risk of thyroid disorder
Prescribing 2 anticholinergics
with both of them strong
or moderate









Increased risk of adverse
effects
A medication with medium/
high anticholinergic activity
prescribed to a patient
aged ≥65 years
6 mo Patients aged ≥65 years before
the start of the 6-month
period
Prescribed any medication with
medium/high anticholinergic
activity during the 6-mo
period
Risk of falling and fracture, risk
of acute confusion, urinary
retention
Warfarin prescribed with any
antibiotic without INR
monitoring within 5 days
6 mo Prescribing warfarin and a
concomitant antibiotic during
the 6-month period
No record of INR monitoring
test within 5 d of
combination being prescribed
during the 6-mo period
Increased risk of bleeding





6 mo Prescribed warfarin or NSAID
during the 6-month period
Prescribed warfarin and
concurrently prescribed
NSAID during the 6-mo
period
Increased risk of bleeding




6 mo Prescribed antiplatelet and
NSAID during the 6-month
period
Not prescribed gastrointestinal
protection during the 6-mo
period
Increased risk of bleeding
Four or more psychotropics
prescribed to a patient for
>3 months
6 mo Prescribed 3 psychotropics
concurrently during the 6-
month period
Prescribed 4 or more
psychotropics concurrently
for 3 mo during the 6-mo
period (any 3 mo, does not
have to be sequential)
Increased risk of adverse
effects
Three or more psychotropic
drugs prescribed on a PRN
basis
6 mo Prescribed 2 psychotropics as
PRN during the 6-month
period
Prescribed 3 or more
psychotropics as PRN during
the 6-mo period
Increased risk of adverse
effects
NSAID: nonsteroidal anti-inflammatory drugs; SSRI/SNRI: selective serotonin reuptake inhibitor/selective norepinephrine reuptake inhibitor; ACEi/ARB:
angiotensin converting enzyme inhibitor/angiotensin receptor blocker; NOAC/DOAC: novel oral anticoagulants/direct oral anticoagulants; U&E: urea and
electrolytes; INR, international normalised ratio; PRN, pro re nata (as required).
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